Skip to main content
. 2005 Dec;142(3):548–554. doi: 10.1111/j.1365-2249.2005.02946.x

Table 1. Characteristics of the study population and several subpopulations.

All females:n(%) Group Ia: n(%) Group IIb: n(%) Group IIIc: n(%)
Race
″African American 297 (75·0) 209 (74·4) 80 (83·3) 75 (77·3)
″Other 99 (25·0) 72 (25·6) 16 (16·7) 22 (22·7)
Age at enrolment
″< 17 years 144 (36·4) 108 (38·4) 44 (45·8) 47 (48·5)e*
″≥ 17 years 252 (63·6) 173 (61·6) 52 (54·2) 50 (51·5)
Sexual partners
″< 2 297 (75·0) 210 (74·7) 70 (72·9) 63 (64·9)e*
″≥ 2 99 (25·0) 71 (25·3) 26 (27·1) 34 (35·1)
HIV-1 infection
″Seropositive 254 (64·1) 195 (69·4) 60 (62·5) 58 (59·8)
″Seronegative 142 (35·9) 86 (30·6) 36 (37·5) 39 (40·2)
Oral contraceptive in past 3 monthsd
″No 219 (51·6) 160 (57·8) 51 (54·3) 56 (59·0)
″Yes 168 (43·4) 117 (42·2) 43 (45·7) 39 (41·1)
Genital wartsd
″No 292 (80·2) 204 (78·2) 77 (89·5) 73 (84·9)
″Yes 72 (19·8) 57 (21·8) 9 (10·5) 13 (15·1)
Prior chlamydial infectiond
″No 232 (63·7) 157 (60·1) 49 (57·0) 47 (54·6)
″Yes 132 (36·3) 104 (39·9) 37 (43·0) 39 (45·4)
Gonorrhoead
″No 281 (77·2) 194 (74·3) 61 (70·9) 65 (75·6)
″Yes 83 (22·8) 67 (25·7) 25 (29·1) 21 (24·4)
Bacterial vaginosisd
″No 277 (76·1) 196 (75·1) 65 (75·6) 68 (79·1)
″Yes 87 (23·9) 65 (24·9) 21 (24·4) 18 (20·9)
CD4+ T cells count (cells/µl)d
″< 400 83 (21·5) 58 (21·1) 10 (10·8)e* 9 (9·5)e**
″≥ 400 304 (78·6) 217 (78·9) 83 (89·2) 86 (90·5)
a

Subjects with at least four visits of endocervical cytokine data available (Group I).

b

Subjects who acquired Chlamydia trachomatis within two consecutive visits (C. trachomatis negative visit followed immediately by C. trachomatis positive visit).

c

Subjects cleared C. trachomatis infection within two consecutive visits (C. trachomatis positive visit followed immediately by C. trachomatis negative visit).

d

Few subjects had missing information.

e

P < 0·05 (*) or P < 0·01 (**) compared with all subjects.